- Home
- DOYU vs TLSI Comparison
DOYU vs TLSI Comparison
Compare DOYU & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOYU
- TLSI
- Stock Information
- Founded
- DOYU 2014
- TLSI 2010
- Country
- DOYU China
- TLSI United States
- Employees
- DOYU N/A
- TLSI N/A
- Industry
- DOYU Computer Software: Programming Data Processing
- TLSI Medical Specialities
- Sector
- DOYU Technology
- TLSI Health Care
- Exchange
- DOYU Nasdaq
- TLSI Nasdaq
- Market Cap
- DOYU 195.9M
- TLSI 204.0M
- IPO Year
- DOYU 2019
- TLSI N/A
- Fundamental
- Price
- DOYU $7.31
- TLSI $4.89
- Analyst Decision
- DOYU Hold
- TLSI Strong Buy
- Analyst Count
- DOYU 1
- TLSI 5
- Target Price
- DOYU $7.00
- TLSI $10.90
- AVG Volume (30 Days)
- DOYU 49.3K
- TLSI 153.7K
- Earning Date
- DOYU 05-20-2025
- TLSI 08-13-2025
- Dividend Yield
- DOYU 271.09%
- TLSI N/A
- EPS Growth
- DOYU N/A
- TLSI N/A
- EPS
- DOYU N/A
- TLSI N/A
- Revenue
- DOYU $575,786,186.00
- TLSI $32,141,000.00
- Revenue This Year
- DOYU N/A
- TLSI $55.52
- Revenue Next Year
- DOYU N/A
- TLSI $54.76
- P/E Ratio
- DOYU N/A
- TLSI N/A
- Revenue Growth
- DOYU N/A
- TLSI 46.20
- 52 Week Low
- DOYU $5.68
- TLSI $3.50
- 52 Week High
- DOYU $20.17
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- DOYU 61.50
- TLSI 42.89
- Support Level
- DOYU $7.05
- TLSI $4.85
- Resistance Level
- DOYU $7.44
- TLSI $5.11
- Average True Range (ATR)
- DOYU 0.29
- TLSI 0.30
- MACD
- DOYU 0.09
- TLSI -0.03
- Stochastic Oscillator
- DOYU 72.18
- TLSI 13.45
About DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.